Background
Data regarding multidrug-resistant (MDR) Acinetobacter baumannii infections among cancer patients are limited.
Methods
We conducted a case-control study to investigate the risk factors for acquisition
of MDR A baumannii and the outcomes among cancer patients. Cases were inpatients with malignancy who
had MDR A baumannii from any cultures between 2008 and 2011. Controls were inpatients with malignancy
but no MDR A baumannii.
Results
A total of 31 case patients were matched with 62 control patients. Hematologic malignancy
(P = .036), need for dialysis (P = .01), admission for other reasons except elective surgery (P = .03), transfer from other health care facilities (P = .02), prolonged intensive care unit stay (P = .004), mechanical ventilation (P < .001), pressor use (P = .001), tube feeding (P < .001), transfusion (P = .009), and prior antimicrobial use (P < .001) were identified as significant risk factors in univariate analysis. Need
for dialysis (odds ratio [OR], 18.23; P = .04) and prolonged intensive care unit stay (OR, 19.28; P = .01) remained significant in multivariate analysis. Lengths of stay were 28 days
for the case patients and 10 days for the control patients (P = .001). The 90-day mortality rates were 41.9% and 29.0%, respectively (P = .20).
Conclusions
Acquisition of MDR A baumannii among cancer patients appears to be associated with general nosocomial infection
risk factors rather than underlying malignancies.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Infection ControlAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.Clin Infect Dis. 2011; 52: e56-e93
- Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.J Antimicrob Chemother. 2008; 61: 721-728
- Acinetobacter: an old friend, but a new enemy.J Hosp Infect. 2009; 73: 355-363
- Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.Infect Control Hosp Epidemiol. 2007; 28: 713-719
- Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients.Intensive Care Med. 2009; 35: 1964-1969
- Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.Int J Infect Dis. 2008; 12: 16-21
- Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.J Microbiol Immunol Infect. 2012; 45: 356-362
- Performance Standards for Antimicrobial Susceptibility Testing Twenty-First Informational Supplement.Clinical and Laboratory Standards Institute, Wayne [PA]2011
- Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU).Res Microbiol. 2011; 162: 393-404
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect. 2012; 18: 268-281
- [Nosocomial pneumonias in haematological malignancies in the medical intensive care unit].Pneumologie. 2003; 57: 73-77
- Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia.Epidemiol Infect. 2010; 138: 1044-1051
- Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients.Braz J Med Biol Res. 2009; 42: 289-293
- Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.Cancer. 2010; 116: 967-973
- Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.Bone Marrow Transplant. 2007; 39: 775-781
- Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections.Eur J Clin Microbiol Infect Dis. 2006; 25: 1-7
- Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study.Crit Care Med. 2007; 35: 1318-1323
- Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality.J Crit Care. 2011; 26: 460-467
- Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach.Am J Infect Control. 2009; 37: 715-722
- Natural history of multidrug-resistant Acinetobacter baumannii carriage in intensive care units.Infect Control Hosp Epidemiol. 2012; 33: 642-643
- Low prevalence of Acinetobacter baumannii colonization on hospital admission.Am J Infect Control. 2010; 38: 329-331
Association for Professionals in Infection Control and Epidemiology. Guide to the elimination of infections in hemodialysis. Available from: http://www.apic.org/Resource_/EliminationGuideForm/7966d850-0c5a-48ae-9090-a1da00bcf988/File/APIC-Hemodialysis.pdf. Accessed May 21, 2013.
- Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.Diagnos Microbiol Infect Dis. 2012; 73: 267-270
- Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States.J Clin Microbiol. 2011; 49: 3849-3854
- Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.J Antimicrob Chemother. 2012; 67: 1607-1615
- Therapeutic options for Acinetobacter baumannii infections: an update.Expert Opin Pharmacother. 2012; 13: 2319-2336
- In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection.Antimicrob Agents Chemother. 2011; 55: 3534-3537
- The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance.Infect Control Hosp Epidemiol. 2005; 26: 346-351
Article info
Publication history
Published online: July 18, 2013
Footnotes
This study was supported by the Thomas H. Nimick Jr. Competitive Research Fund. Y.D. was supported in part by the National Institutes of Health (grant No. K22AI80584) and the Pennsylvania Department of Health (grant No. 4100047864).
Conflicts of interest: Y.D. has received research grants from Merck and has served on an advisory board for Pfizer.
Identification
Copyright
© 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
